456 related articles for article (PubMed ID: 25981607)
1. Deep Vein Thrombosis and Pulmonary Embolism in the Apixaban Era: From Bench to Bedside.
Poredos P; Jezovnik MK
Curr Drug Targets; 2018; 19(6):577-580. PubMed ID: 25981607
[TBL] [Abstract][Full Text] [Related]
2. Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study).
Nakamura M; Nishikawa M; Komuro I; Kitajima I; Uetsuka Y; Yamagami T; Minamiguchi H; Yoshimatsu R; Tanabe K; Matsuoka N; Kanmuri K; Ogawa H
Circ J; 2015; 79(6):1230-6. PubMed ID: 25912695
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial.
Cohen AT; Agnelli G; Buller HR; Gallus A; Raskob GE; Sanders P; Thompson J; Weitz JI
Thromb Haemost; 2019 Mar; 119(3):461-466. PubMed ID: 30650446
[TBL] [Abstract][Full Text] [Related]
4. Apixaban (Eliquis) in deep vein thrombosis and pulmonary embolism. Warfarin remains the standard therapy.
Prescrire Int; 2015 Sep; 24(163):206. PubMed ID: 26417627
[TBL] [Abstract][Full Text] [Related]
5. Oral apixaban for the treatment of acute venous thromboembolism.
Agnelli G; Buller HR; Cohen A; Curto M; Gallus AS; Johnson M; Masiukiewicz U; Pak R; Thompson J; Raskob GE; Weitz JI;
N Engl J Med; 2013 Aug; 369(9):799-808. PubMed ID: 23808982
[TBL] [Abstract][Full Text] [Related]
6. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
Agnelli G; Buller HR; Cohen A; Gallus AS; Lee TC; Pak R; Raskob GE; Weitz JI; Yamabe T
J Thromb Haemost; 2015 Dec; 13(12):2187-91. PubMed ID: 26407753
[TBL] [Abstract][Full Text] [Related]
7. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
Brekelmans MP; Scheres LJ; Bleker SM; Hutten BA; Timmermans A; Büller HR; Middeldorp S
Thromb Haemost; 2017 Apr; 117(4):809-815. PubMed ID: 28180233
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease.
Schafer JH; Casey AL; Dupre KA; Staubes BA
Ann Pharmacother; 2018 Nov; 52(11):1078-1084. PubMed ID: 29871510
[TBL] [Abstract][Full Text] [Related]
9. Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial.
Liu X; Johnson M; Mardekian J; Phatak H; Thompson J; Cohen AT
J Am Heart Assoc; 2015 Dec; 4(12):. PubMed ID: 26627879
[TBL] [Abstract][Full Text] [Related]
10. To Bleed or Not to Bleed: That is the Question. The Side Effects of Apixaban.
Ciccone MM; Zito A; Devito F; Maiello M; Palmiero P
Curr Drug Targets; 2018; 19(6):581-584. PubMed ID: 26424386
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Rollins BM; Silva MA; Donovan JL; Kanaan AO
Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis.
Mokadem ME; Hassan A; Algaby AZ
Vascular; 2021 Oct; 29(5):745-750. PubMed ID: 33153401
[TBL] [Abstract][Full Text] [Related]
13. Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model.
Lester PA; Coleman DM; Diaz JA; Jackson TO; Hawley AE; Mathues AR; Grant BT; Knabb RM; Ramacciotti E; Frost CE; Song Y; Wakefield TW; Myers DD
Arterioscler Thromb Vasc Biol; 2017 May; 37(5):942-948. PubMed ID: 28232327
[TBL] [Abstract][Full Text] [Related]
14. Apixaban: a novel oral inhibitor of factor Xa.
Nutescu E
Am J Health Syst Pharm; 2012 Jul; 69(13):1113-26. PubMed ID: 22722590
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.
; Buller H; Deitchman D; Prins M; Segers A
J Thromb Haemost; 2008 Aug; 6(8):1313-8. PubMed ID: 18541000
[TBL] [Abstract][Full Text] [Related]
16. Impact of oral anticoagulation choice on healthcare utilization for the primary treatment of venous thromboembolism.
Lutsey PL; MacLehose RF; Claxton JS; Walker RF; Adam TJ; Alonso A; Zakai NA
Vasc Med; 2020 Dec; 25(6):549-556. PubMed ID: 32716254
[TBL] [Abstract][Full Text] [Related]
17. Drug Treatment of Venous Thromboembolism in the Elderly.
Boey JP; Gallus A
Drugs Aging; 2016 Jul; 33(7):475-90. PubMed ID: 27255713
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism.
Dawwas GK; Smith SM; Dietrich E; Lo-Ciganic WH; Park H
Am J Health Syst Pharm; 2020 Jan; 77(3):188-195. PubMed ID: 31974557
[TBL] [Abstract][Full Text] [Related]
19. Temporal Trends in the Practice Pattern for Venous Thromboembolism in Japan: Insight From JROAD-DPC.
Yamashita Y; Morimoto T; Yoshikawa Y; Yaku H; Sumita Y; Nakai M; Ono K; Kimura T
J Am Heart Assoc; 2020 Jan; 9(2):e014582. PubMed ID: 31918600
[TBL] [Abstract][Full Text] [Related]
20. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population.
Hlavacek P; Guo JD; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
Curr Med Res Opin; 2019 Dec; 35(12):2043-2051. PubMed ID: 31387467
[No Abstract] [Full Text] [Related]
[Next] [New Search]
